Takeaways: Silo Pharma’s CIPO Notice of Allowance for SPC‑15 strengthens its IP moat around a prophylactic, intranasal 5‑HT4 agonist approach for PTSD and stress‑induced disorders, complementing a rec...
Takeaways: Jupiter’s ALA-002 deal gives it a high-upside, FDA-designated NCE asset in the emerging U.S. psychedelic therapeutics space, expanding the company from one CNS program to two clinical...
